drugset / Trial / NCT02717455
Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
Phase 1
Completed
53 enrolled
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of panobinostat in treating younger patients with diffuse intrinsic pontine glioma (DIPG). Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stratum 1 treats patients with DIPG that has returned or gotten worse (progressed). Stratum 2 treats patients with DIPG or H3K27+Thalamic Diffuse Malignant Glioma (DMG) that has not yet gotten worse.
Timeline
- Start
- 2016-06-28
- Primary completion
- 2022-02-14
- Completion
- 2024-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panobinostat | Small molecule | 5 mg/m2 | Oral |
| Subject | Panobinostat | Small molecule | 10 mg/m2 | Oral |
| Subject | Panobinostat | Small molecule | 16 mg/m2 | Oral |
| Subject | Panobinostat | Small molecule | 22 mg/m2 | Oral |
| Subject | Panobinostat | Small molecule | 28 mg/m2 | Oral |
| Subject | Panobinostat | Small molecule | 36 mg/m2 | Oral |